Table of Contents
Introduction
Lithium is the prototypical mood stabilizer and remains one of the most important drugs for bipolar disorder, especially for acute mania and maintenance therapy. Its exact therapeutic mechanism is not fully defined in humans, and the official prescribing information states that the mechanism of action of lithium as a mood-stabilizing agent is unknown. However, a large body of pharmacologic and experimental evidence shows that lithium influences intracellular signaling, second-messenger systems, neurotransmission, and neuronal plasticity. These actions collectively help stabilize mood and reduce manic relapse in bipolar disorder.
Mechanism of Action (Step-wise)
- Lithium enters excitable cells and interferes with intracellular signal transduction pathways rather than acting through a single classical receptor.
- One major proposed action is inhibition of inositol monophosphatase, which reduces free inositol within central nervous system cells.
- Reduced inositol availability decreases phosphatidylinositol cycle signaling and dampens overactive second-messenger responses in neurons.
- Lithium also inhibits glycogen synthase kinase-3, especially GSK-3β, an enzyme involved in gene transcription, circadian regulation, synaptic plasticity, and cell survival pathways.
- In vivo studies have shown that therapeutically relevant lithium exposure inhibits brain GSK-3 activity, supporting this as an important pharmacologic target.
- Lithium modulates neurotransmission by reducing excessive excitatory signaling, including glutamatergic overactivity and pathologic dopaminergic drive.
- It also supports more stable inhibitory and modulatory signaling, including effects on GABAergic and serotonergic function.
- Through these cellular and network-level effects, lithium reduces manic overactivation, improves long-term mood stability, and may exert neuroprotective effects.
For exams, the safest way to write the MOA is that lithium’s exact mechanism is unknown, but it is believed to act mainly through inositol depletion and inhibition of GSK-3, with downstream effects on second-messenger pathways and neurotransmission.
Pharmacokinetics
Lithium is well absorbed after oral administration and is reported to be completely absorbed in the upper gastrointestinal tract. Peak serum concentrations occur about 0.25 to 3 hours after immediate-release preparations and 2 to 6 hours after sustained-release preparations. It has negligible plasma protein binding and a volume of distribution approximating total body water, about 0.7 to 1 L/kg after equilibrium. Lithium is not metabolized. It is eliminated primarily by the kidneys, with about 80% of filtered lithium reabsorbed in the proximal tubule. Its elimination half-life is approximately 18 to 36 hours, so serum level monitoring is essential, especially when renal function changes.
Because lithium is cleared renally, dehydration, sodium depletion, diuretics, and renal impairment can substantially raise lithium concentrations and predispose to toxicity. This pharmacokinetic profile explains why fluid balance, renal function, and serum lithium levels are central to safe prescribing.
Clinical Uses
Lithium is indicated for the treatment of manic episodes of bipolar disorder and for maintenance treatment in individuals with bipolar disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of episodes that still occur. In routine clinical pharmacology, it is best remembered as a classic mood stabilizer for bipolar disorder, particularly for acute mania and long-term relapse prevention.
Important exam-oriented uses include:
Acute mania in bipolar disorder
Maintenance therapy in bipolar disorder
Long-term mood stabilization in recurrent bipolar illness
Adverse Effects
Common adverse effects of lithium include fine hand tremor, polyuria, mild thirst, nausea, and general discomfort during initial treatment. These are high-yield adverse effects that frequently appear in exams.
Chronic lithium therapy can impair renal concentrating ability and may produce nephrogenic diabetes insipidus with polyuria and polydipsia. Lithium can also affect the thyroid, where it is concentrated and can inhibit thyroid synthesis and release, leading to hypothyroidism. Long-term therapy has also been associated with hypercalcemia and hyperparathyroidism.
Lithium toxicity is an important clinical concern and is more likely with dehydration, renal dysfunction, sodium depletion, and interacting drugs that reduce lithium clearance. Pregnancy also requires caution because lithium may cause fetal harm, and serum levels must be carefully monitored if therapy is continued.
Comparative Analysis
| Feature | Lithium | Valproate | Carbamazepine |
|---|---|---|---|
| Drug class | Mood stabilizer | Anticonvulsant mood stabilizer | Anticonvulsant mood stabilizer |
| Core mechanism | Exact MOA unknown; inositol depletion and GSK-3 inhibition are major proposed mechanisms | Increases GABA activity and modulates ion channels | Blocks voltage-gated sodium channels |
| Main role in bipolar disorder | Acute mania and maintenance | Acute mania and maintenance | Acute mania and maintenance in selected patients |
| Elimination | Renal | Hepatic metabolism | Hepatic metabolism |
| Major monitoring | Serum lithium, renal function, thyroid function | Liver function, platelets | CBC, liver function, drug interactions |
| Classic adverse effects | Tremor, polyuria, hypothyroidism, nephrogenic diabetes insipidus | Weight gain, hepatotoxicity, tremor | Diplopia, ataxia, leukopenia, rash |
| Pregnancy concern | Fetal harm risk | Teratogenic risk | Teratogenic risk |
Lithium differs from valproate and carbamazepine because it is a simple ion with a unique intracellular signaling profile and is eliminated almost entirely by the kidneys rather than by hepatic metabolism. In pharmacology exams, lithium is especially associated with tremor, polyuria, hypothyroidism, nephrogenic diabetes insipidus, and the need for serum drug level monitoring.
MCQs
- Lithium is primarily used as a:
a) Antidepressant
b) Mood stabilizer
c) Antipsychotic
d) Sedative
Answer: b) Mood stabilizer
- The official labeling of lithium states that its mood-stabilizing mechanism is:
a) Fully understood
b) Unknown
c) Purely dopamine blockade
d) Purely serotonin reuptake inhibition
Answer: b) Unknown
- One important proposed mechanism of lithium is inhibition of:
a) Acetylcholinesterase
b) Monoamine oxidase
c) Inositol monophosphatase
d) Cyclooxygenase
Answer: c) Inositol monophosphatase
- Lithium has been shown in vivo to inhibit which enzyme?
a) Carbonic anhydrase
b) Glycogen synthase kinase-3
c) Xanthine oxidase
d) Aromatase
Answer: b) Glycogen synthase kinase-3
- Lithium is mainly indicated for:
a) Bipolar disorder
b) Schizophrenia only
c) Generalized anxiety disorder only
d) Parkinson disease
Answer: a) Bipolar disorder
- Lithium is eliminated primarily through the:
a) Liver
b) Lungs
c) Kidney
d) Intestine
Answer: c) Kidney
- Which of the following is a common adverse effect of lithium?
a) Severe constipation
b) Fine hand tremor
c) Gingival hyperplasia
d) Bronchospasm
Answer: b) Fine hand tremor
- Chronic lithium therapy may cause:
a) Nephrogenic diabetes insipidus
b) Hypoglycemia
c) Peptic ulcer disease
d) Cataract
Answer: a) Nephrogenic diabetes insipidus
- Lithium can inhibit thyroid hormone synthesis and release, leading to:
a) Hypercortisolism
b) Hypothyroidism
c) Hyperaldosteronism
d) Acromegaly
Answer: b) Hypothyroidism
- A major reason for serum lithium monitoring is that lithium:
a) Has no renal excretion
b) Is highly protein bound
c) Has a narrow therapeutic range and renal clearance dependence
d) Is rapidly destroyed in the stomach
Answer: c) Has a narrow therapeutic range and renal clearance dependence
- Peak serum concentration after immediate-release lithium generally occurs within:
a) 0.25 to 3 hours
b) 8 to 12 hours
c) 24 hours
d) 48 hours
Answer: a) 0.25 to 3 hours
- Which condition increases the risk of lithium toxicity?
a) Good hydration
b) Sodium depletion
c) Normal renal function
d) High protein intake
Answer: b) Sodium depletion
FAQs
What is the exact mechanism of action of lithium?
The exact mechanism is not fully known. Current evidence supports effects on intracellular signaling, especially inositol depletion and inhibition of GSK-3.
Why is lithium called a mood stabilizer?
It is used in bipolar disorder to treat mania and reduce recurrence of mood episodes during maintenance therapy.
Why does lithium cause polyuria?
Lithium can reduce renal concentrating ability and may cause nephrogenic diabetes insipidus, which presents with polyuria and polydipsia.
Why should thyroid function be monitored during lithium therapy?
Lithium is concentrated in the thyroid and can inhibit thyroid synthesis and release, leading to hypothyroidism.
Why are serum lithium levels important?
Lithium is cleared by the kidneys, not metabolized, and toxicity risk rises when renal function worsens or sodium and water balance changes.
Can lithium be used in pregnancy?
It may cause fetal harm and requires careful risk-benefit assessment and close monitoring if continued during pregnancy.
References
Goodman & Gilman’s The Pharmacological Basis of Therapeutics – Neuropharmacology Section
Katzung: Basic and Clinical Pharmacology – Antipsychotic Agents & Lithium
Tripathi: Essentials of Medical Pharmacology – Mood Stabilizers
Harrison’s Principles of Internal Medicine – Bipolar Disorder
